Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received an order from the Assistant Director, Drugs Control Administration (Zone III, Tamil Nadu) suspending the drug license of one store located at MGR Nagar for three days. The order was received on July 22, 2025, citing Rule 65 of the Drugs and Cosmetics Act, 1940, and the corresponding Rules, 1945. The company has disclosed a potential revenue loss of approximately Rs 3.03 lakhs from this three-day suspension. The disclosure was made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements, 2015.
The financial impact is minimal — roughly Rs 3.03 lakhs in potential lost revenue from a single store for just three days, which is immaterial for a large pharmacy chain like MedPlus. Shareholders are unlikely to see any meaningful effect on the stock price or overall business operations.